



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of

MARGEL et al.

Atty. Ref.: 4110-40; Confirmation No. 7014

Appl. No. 10/534,469

TC/A.U. 1651

Filed: May 11, 2005

Examiner: R. Davis

For: BIOLOGICAL GLUE BASED ON THROMBIN-CONJUGATED  
NANOPARTICLES

\* \* \* \* \*

October 29, 2007

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**RESPONSE TO RESTRICTION REQUIREMENT**

Responsive to the Official Action of August 30, 2007 (for which petition is hereby made for a one month extension of time), and the requirement for restriction presented in it, holding the subject matter of Group I (claims 1-9 and 15-19), Group II (claims 10-14, 20-24 and 28), or Group III (claims 25-27), Applicants hereby elect the invention of Group I (claims 1-9 and 15-19) for further substantive examination.

This election is made without traverse. However, since a restriction requirement is never proper unless the restricted group of claims is patentably distinct (*i.e.*, inter alia, nonobvious under 35 U.S.C. §103) from the elected group of claims, the Examiner is

10/30/2007 SZEWDIE1 00000073 10534469

01 FC:2251

60.00 0P

MARGE~~L~~ et al.  
Appl. No. 10/534,469  
October 29, 2007


requested to ensure that such patentable distinctness is present before proceeding to make the requirement final.

It is respectfully requested that the non-elected claims be retained for use with a possible divisional application.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_

  
Joseph S. Presta  
Reg. No. 35,329

JSP:mg  
901 North Glebe Road, 11th Floor  
Arlington, VA 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100